萆菟汤治疗慢性非细菌性前列腺炎110例

目的 观察萆菟汤治疗慢性非细菌性前列腺炎(chronic abacterial prostatitis，CAP)的临床疗效。方法 将176例CAP患者随机分为治疗组110例和对照组66例，分别采用萆菟汤和前列康片治疗，疗程均为8周。观察并比较两组临床疗效，治疗前后分别观察两组NIH- CPSI评分，并进行挤压前列腺分泌液（expressed prostatic secretion，EPS）常规检查。结果 治疗组临床疗效明显优于对照组（P<0.05）。与治疗前比较，两组治疗后NIH- CPSI的疼痛症状、排尿症状、生活质量评分和总分均显著降低（P<0.05），治疗组上述评分降低值显著大于对照组（P<0.05）。与治疗前比较，两组治疗后EPS中白细胞计数及pH值均显著降低（P<0.05），卵磷脂小体计数均显著升高（P<0.05）；治疗组治疗后白细胞计数降低值小于对照组（P<0.05），卵磷脂小体升高值和pH值降低值大于对照组（P＜0.05）。结论 萆菟汤对CAP具有显著的临床疗效。

Clinical Efficacy of Bitu Decoction in Treatment of Chronic Abacterial Prostatitis: A Report of 110 Cases

Objective To observe the clinical efficacy of Bitu Decoction in the treatment of chronic abacterial prostatitis (CAP). Methods A total of 176 CAP patients were randomly divided into control group (n=66) and treatment group (n=110). The treatment group received Bitu Decoction, while the control group received Qianliekang Tablet. The course of treatment was 8 weeks for both groups. The treatment outcome was compared between the two groups; before and after treatment, the National Institutes of Health Chronic Prostatitis Symptom Index (NIH- CPSI) scores of the two groups were determined, and expressed prostatic secretion (EPS) examination was performed. Results The treatment group had a significantly better treatment outcome than the control group (P<0.05). After treatment, both groups showed significant decreases in the pain, urinary, and quality of life scores and total score of NIH- CPSI (P<0.05), and the treatment group had significantly higher decreases in the above scores than the control group (P<0.05). In addition, the two groups had significantly reduced white blood cell (WBC) count and pH value (P<0.05) but significantly increased small particles of lecithin (SPL) (P<0.05) in EPS examination; compared with the control group, the treatment group had a significantly lower decrease in WBC count (P<0.05), a significantly higher increase in SPL (P<0.05), and a significantly higher decrease in pH value (P<0.05). Conclusion Bitu Decoction has significant clinical efficacy in the treatment of CAP.